Effect of Immune Reconstitution on the Incidence of HIV-Related Hodgkin Lymphoma

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Kowalkowski, Marc A ^a,b   Mims, Martha P ^a   Amiran, E Susan ^a   Lulla, Premal ^a   Chiao, Elizabeth Y ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; EPSTEIN BARR VIRUS; FOLLOW UP; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETROSPECTIVE STUDY; RNA ANALYSIS; SOLDIER; VETERAN;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COMORBIDITY; HIV INFECTIONS; HIV-1; HODGKIN DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VETERANS; VIRAL LOAD;

EID: 84884872714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077409     Document Type: Article

References (36)

1. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, et al. (2005) Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97(6):: 425-432. doi:10.1093/jnci/dji072. PubMed: 15770006.
2. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, et al. (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30: S5-14. doi:10.1086/313843. PubMed: 10770911.
3. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, et al. (2003) Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21(18):: 3447-3453. doi:10.1200/JCO.2003.01.096. PubMed: 12972519.
4. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, et al. (2006) Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20(12):: 1645-1654. doi:10.1097/01.aids.0000238411.75324.59. PubMed: 16868446.
5. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, et al. (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):: 753-762. doi:10.1093/jnci/djr076. PubMed: 21483021.
6. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM, (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581):: 59-67. doi:10.1016/S0140-6736(07)61050-2. PubMed: 17617273.
7. Shiels MS, Cole SR, Kirk GD, Poole C, (2009) A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52(5):: 611-622. doi:10.1097/QAI.0b013e3181b327ca. PubMed: 19770804.
8. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC, (2009) Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 52(2):: 203-208. doi:10.1097/QAI.0b013e3181b033ab. PubMed: 19617846.
9. Frisch M, Biggar RJ, Engels EA, Goedert JJ, (2001) Association of cancer with AIDS-related immunosuppression in adults. JAMA 285(13):: 1736-1745. doi:10.1001/jama.285.13.1736. PubMed: 11277828.
10. Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, et al. (2011) HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes. Blood 117(23):: 6100-6108. doi:10.1182/blood-2010-08-301531. PubMed: 21368291.
11. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S, (2007) The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 165(10):: 1143-1153. doi:10.1093/aje/kwm017. PubMed: 17344204.
12. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, et al. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148(10):: 728-736. doi:10.7326/0003-4819-148-10-200805200-00005. PubMed: 18490686.
13. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, et al. (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27(6):: 884-890. doi:10.1200/JCO.2008.19.6626. PubMed: 19114688.
14. Engels EA, (2009) Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 23(8):: 875-885. doi:10.1097/QAD.0b013e328329216a. PubMed: 19349851.
15. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA, (2006) Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108(12):: 3786-3791. doi:10.1182/blood-2006-05-024109. PubMed: 16917006.
16. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 10(12):: 1152-1159. doi:10.1016/S1470-2045(09)70282-7. PubMed: 19818686.
17. Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, et al. (2009) Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 113(23):: 5737-5742. doi:10.1182/blood-2009-02-204172. PubMed: 19336755.
18. Backus L, Mole L, Chang S, Deyton L, (2001) The Immunology Case Registry. J Clin Epidemiol 54: S12-S15. doi:10.1016/S0895-4356(01)00442-5. PubMed: 11750204.
19. Backus LI, Gavrilov S, Loomis TP, Halloran JP, Phillips BR, et al. (2009) Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 16(6):: 775-783. doi:10.1197/jamia.M3203. PubMed: 19717794.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR, (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):: 373-383. doi:10.1016/0021-9681(87)90171-8. PubMed: 3558716.
21. Deyo RA, Cherkin DC, Ciol MA, (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):: 613-619. doi:10.1016/0895-4356(92)90133-8. PubMed: 1607900.
22. Levine A, (2006) Hodgkin lymphoma: To the HAART of the Matter. Blood 108: 3630-3631. doi:10.1182/blood-2006-09-047498.
23. Carbone A, Gloghini A, Serraino D, Spina M, (2009) HIV-associated Hodgkin lymphoma. Curr Opin HIV Aids 4(1):: 3-10. doi:10.1097/COH.0b013e32831a722b. PubMed: 19339934.
24. Gloghini A, Carbone A, (2007) Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? Int J Cancer 120(12):: 2753-2754. doi:10.1002/ijc.22650. PubMed: 17330236.
25. Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, et al. (2011) HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood 118(1):: 44-49. doi:10.1182/blood-2011-02-339275. PubMed: 21551234.
26. Dolcetti R, Boiocchi M, Gloghini A, Carbone A, (2001) Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer 37(10):: 1276-1287. doi:10.1016/S0959-8049(01)00105-8. PubMed: 11423259.
27. Kutok JL, Wang F, (2006) Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 1: 375-404. doi:10.1146/annurev.pathol.1.110304.100209. PubMed: 18039120.
28. Friis AM, Gyllensten K, Aleman A, Ernberg I, Akerlund B, (2010) The Effect of Antiretroviral Combination Treatment on Epstein-Barr Virus (EBV) Genome Load in HIV-Infected Patients. Viruses 2(4):: 867-879. doi:10.3390/v2040867. PubMed: 21994658.
29. Righetti E, Ballon G, Ometto L, Cattelan AM, Menin C, et al. (2002) Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 16(1):: 63-73. doi:10.1097/00002030-200201040-00009. PubMed: 11741164.
30. Regidor DL, Detels R, Breen EC, Widney DP, Jacobson LP, et al. (2011) Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 25(3):: 303-314. doi:10.1097/QAD.0b013e32834273ad. PubMed: 21192231.
31. Douek DC, Roederer M, Koup RA, (2009) Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60: 471-484. doi:10.1146/annurev.med.60.041807.123549. PubMed: 18947296.
32. Mahnke YD, Greenwald JH, DerSimonian R, Roby G, Antonelli LR, et al. (2012) Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 119(13):: 3105-3112. doi:10.1182/blood-2011-09-380840. PubMed: 22219223.
33. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, et al. (2010) Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLOS Med 7(12):: e1000384. PubMed: 21253011.
34. Sereti I, Rodger AJ, French MA, (2010) Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV Aids 5(6):: 504-510. doi:10.1097/COH.0b013e32833ed774. PubMed: 20966640.
35. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB, (2005) The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 100(1):: 56-63. doi:10.1111/j.1572-0241.2005.40670.x. PubMed: 15654781.
36. Chiao EY, Giordano TP, Richardson P, El-Serag HB, (2008) Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 26(3):: 474-479. doi:10.1200/JCO.2007.14.2810. PubMed: 18202423.